Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

NCT03749213 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

EGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.